SEC Comment Letter 0000000000-24-006188 to BIORA THERAPEUTICS, INC. (BIOR) (CIK 0001580063)

BIORA THERAPEUTICS, INC. (BIOR) (CIK 0001580063)
Date: May 29, 2024 · CIK: 0001580063 · Accession: 0000000000-24-006188

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-279540

Date

May 29, 2024

Author

Division of Corporation Finance

Form

UPLOAD

Company

BIORA THERAPEUTICS, INC. (BIOR) (CIK 0001580063)

Letter

United States securities and exchange commission logo May 29, 2024 Aditya P. Mohanty Chief Executive Officer Biora Therapeutics, Inc. 4330 La Jolla Village Drive, Suite 300 San Diego, CA 92122

Re: Biora Therapeutics, Inc. Registration Statement on Form S-3 Filed May 20, 2024 File No. 333-279540

Dear Aditya P. Mohanty:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Chris Edwards at 202-551-6761 with any questions.

Sincerely,
Division of Corporation Finance

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
United States securities and exchange commission logo

                          May 29, 2024

       Aditya P. Mohanty
       Chief Executive Officer
       Biora Therapeutics, Inc.
       4330 La Jolla Village Drive, Suite 300
       San Diego, CA 92122

                                                        Re: Biora Therapeutics,
Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed May 20, 2024
                                                            File No. 333-279540

       Dear Aditya P. Mohanty:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Chris
Edwards at 202-551-6761 with any questions.

                          Sincerely,

                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Branden C. Berns
</TEXT>
</DOCUMENT>

SecProbe.io